Drug profile · INN
incobotulinumtoxina
XEOMIN
incobotulinumtoxina (XEOMIN) is a synaptosomal-associated protein 25 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — incobotulinumtoxina
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 8
- Data quality
- 0.84
Quick answer
incobotulinumtoxina (XEOMIN) is a synaptosomal-associated protein 25 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Synaptosomal-associated protein 25 inhibitor
Primary target: Synaptosomal-associated protein 25
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is incobotulinumtoxina?
incobotulinumtoxina (XEOMIN) is a synaptosomal-associated protein 25 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for incobotulinumtoxina?
XEOMIN is a marketed brand name for incobotulinumtoxina. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of incobotulinumtoxina?
incobotulinumtoxina has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.